01053-X/asset/826330f0-5581-4d6d-8f45-2192fe6ac242/main.assets/gr2_lrg.jpg)
glp 1 agonist retatrutide Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA Retatrutide vs semaglutide: complete comparison
Description
The management of Type 2 Diabetes has seen significant advancements with the introduction of oral Semaglutide GLP-1 (Rybelsus)
The GLP-1 market is projected to reach an estimated 31.5 million users by 2035
This continued vigilance is paramount to patient safety
Going slower beats fighting through
This is particularly true for people with hemophilic arthropathy (joint damage), which can make movement and exercise more difficult
